Vistabel: Botulinum Toxin Type A by Allergan for Aesthetic Treatment
Overview: Vistabel (AbobotulinumtoxinA)
Vistabel is the brand name for AbobotulinumtoxinA (formerly Botulinum Toxin Type A) from Swiss pharmaceutical company Galderma for aesthetic indications in Europe. The identical product is marketed as Dysport for therapeutic (medical) indications. Vistabel was approved by the European Medicines Agency (EMA) in 2001 for the aesthetic treatment of glabellar lines (frown lines) in adults, making it one of the first botulinum toxin preparations with European approval for aesthetic purposes.
AbobotulinumtoxinA differs from OnabotulinumtoxinA (Botox/Vistabex) in its formulation and dosage units: Vistabel units are not directly comparable to Botox units (typical conversion ratio: 2.5 to 3 Vistabel units correspond to 1 Botox unit). This must be taken into account when dosing.
Active Substance and Mechanism
AbobotulinumtoxinA is a purified neurotoxin produced from the bacterium Clostridium botulinum Type A. It reversibly blocks neuromuscular transmission by inhibiting acetylcholine release at the motor endplate. The active substance cleaves the SNAP-25 protein (Synaptosomal-Associated Protein 25) required for the fusion of acetylcholine vesicles with the presynaptic membrane. Without acetylcholine release, the muscle cannot contract, leading to temporary, completely reversible muscle relaxation.
The effect begins 2 to 5 days after injection, reaches its maximum at 10 to 14 days, and lasts 3 to 6 months. Reversibility is due to the regeneration of new neuromuscular junctions.
Indications
Approved aesthetic indication (EMA/EU): Temporary improvement of moderate to severe glabellar lines (frown lines between the eyebrows) in adults up to 65 years.
Commonly used off-label for: Forehead lines, crow's feet (periocular wrinkles), Bunny Lines (nasal wrinkles), Platysma banding (neck wrinkles), brow lift, hyperhidrosis (sweating) axillary or palmar, bruxism (teeth grinding, masseter injection), lip flip, and gummy smile correction.
Treatment Protocol
Vistabel injections are performed outpatient without anesthesia or with topical numbing cream. Treatment duration: 10 to 20 minutes. Fine injection needles are inserted directly into the target muscle. Post-treatment: no exercise for 24 hours, no rubbing, no lying down for 4 hours. Results visible after 2 to 5 days; 2-week follow-up recommended.
Results
Clinical studies show that AbobotulinumtoxinA (Vistabel) at the approved dose (50 units for glabellar lines) leads to notable to complete improvement of glabellar lines in over 80% of patients. Results last 3 to 6 months before retreatment is needed. Regular treatments can lead to long-term weakening of wrinkles as muscles atrophy through chronic inactivity.
Safety
Vistabel is an approved drug with documented safety profile. Common side effects: headache (10 to 15%), local reactions (redness, swelling, mild bruising). Rare complications: ptosis (eyelid drooping) with incorrect injection technique, diplopia, facial weakness. Contraindications: pregnancy, breastfeeding, neuromuscular diseases (myasthenia gravis, Lambert-Eaton syndrome), aminoglycoside antibiotic use. Prescription-only medication.
Costs
Vistabel treatments for glabellar lines: €200 to €500 depending on physician, region, and dosage. Forehead + glabella + crow's feet (3-area treatment): €400 to €800. Health insurance does not cover aesthetic botulinum toxin treatments.